CMPX · NASDAQ · Biotechnology

Compass Therapeutics (CMPX)

Develops oncology antibody candidates for tumor microenvironment biology.

$2.46
Pre-market+0.02 (+1.03%)
At close$2.44(+5.41%)

Something off on this page? Send us feedback.

Next report
Nov 4, 2026
estimated · in 62 days
EPS estimate
−$0.12
Revenue estimate
$229.3K
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.11−$0.12−$0.14−$0.08−$0.09−$0.10−$0.13Pending
Estimate−$0.10−$0.12−$0.13−$0.14−$0.10−$0.10−$0.11−$0.12
Surprise−10.0%0.0%−7.7%+42.9%+10.0%0.0%−17.5%

RevenueReportedEstimate

Feb '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$736.0KPending
Estimate−$900.0K−$818.2K−$600.0K$229.3K
Surprise+222.7%

History

DateEstimateReportedSurprise
Nov 2026−$0.12
Aug 2026−$0.11−$0.13−17.5%
May 2026−$0.10−$0.100.0%
Mar 2026−$0.10−$0.09+10.0%
Nov 2025−$0.14−$0.08+42.9%

The latest year is open to everyone — the 26 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
Apr 2021
Mar 2021
Mar 2021
Aug 2020
Jun 2020
Feb 2020
Nov 2019
Aug 2019
Jul 2019
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 4, 2026−$0.12$229.3K
Aug 6, 2026−$0.11−$0.13−17.5%−$600.0K$736.0K+222.7%+5.3%
May 5, 2026−$0.10−$0.100.0%−$818.2K−4.1%
Mar 5, 2026−$0.10−$0.09+10.0%−$900.0K−0.4%
Nov 5, 2025−$0.14−$0.08+42.9%+4.7%

The latest year is open to everyone — the 26 quarters behind it read with an account.

Sign in
Aug 11, 2025
May 8, 2025
Feb 27, 2025
Nov 12, 2024
Aug 12, 2024
May 13, 2024
Mar 21, 2024
Nov 9, 2023
Aug 3, 2023
May 4, 2023
Mar 15, 2023
Nov 9, 2022
Aug 1, 2022
May 9, 2022
Mar 21, 2022
Nov 12, 2021
Aug 16, 2021
Apr 30, 2021
Mar 11, 2021
Mar 5, 2021
Aug 13, 2020
Jun 8, 2020
Feb 13, 2020
Nov 13, 2019
Aug 13, 2019
Jul 1, 2019